Who are IV paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Docetaxel (D), Paclitaxel (albumin-bound), Docetaxel (DOC), Paclitaxel protein bound, Docetaxel or albumin paclitaxel, VLI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/iv-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

IV paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IV paclitaxel (IV paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule stabilizer. Area: Oncology.

phase 3 Taxane; microtubule stabilizer β-tubulin Oncology Small molecule Live · refreshed every 30 min

Target snapshot

IV paclitaxel (IV paclitaxel) — Athenex, Inc.. IV paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and halting cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
IV paclitaxel TARGET	IV paclitaxel	Athenex, Inc.	phase 3	Taxane; microtubule stabilizer	β-tubulin
Docetaxel (D)	Docetaxel (D)	BeyondSpring Pharmaceuticals Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel (albumin-bound)	Paclitaxel (albumin-bound)	Dai, Guanghai	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel protein bound	Paclitaxel protein bound	Barts & The London NHS Trust	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Docetaxel or albumin paclitaxel	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
VLI	VLI	Spectrum Pharmaceuticals, Inc	marketed	Vinca alkaloid	β-tubulin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule stabilizer class)

Sanofi · 2 drugs in this class
Aravive, Inc. · 1 drug in this class
Athenex, Inc. · 1 drug in this class
Barts & The London NHS Trust · 1 drug in this class
BeyondSpring Pharmaceuticals Inc. · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Dai, Guanghai · 1 drug in this class
Fujian Medical University · 1 drug in this class
Guangzhou Double Bioproducts Co., Ltd · 1 drug in this class
H. Lee Moffitt Cancer Center and Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IV paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/iv-paclitaxel. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing